Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Irinotecan Hydrochloride,Apisolex
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Welton Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The license will allow Welton to use the Apisolex excipient worldwide to develop and commercialize a novel formulation of WP-038 (SN-38) to treat colorectal and associated gastro-intestinal cancers.
Brand Name : WP-038
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 20, 2023
Lead Product(s) : Irinotecan Hydrochloride,Apisolex
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Welton Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Segesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Population Council
Deal Size : Undisclosed
Deal Type : Partnership
Lubrizol Expands Partnership with the Population Council
Details : This builds on a decades-long partnership between the two organizations to optimize the delivery of several vaginal products, including the Population Council’s proprietary progestin, Nestorone®, and MIV-150, and manufacturing lead formulations for to...
Brand Name : Nestorone
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 15, 2020
Lead Product(s) : Segesterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Population Council
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?
Reset All
